Rituxmab Versus IL-6 in Treating ILD

• Status: Completed
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

All SSc patients should know if they have been diagnosed with interstitial lung disease, or pulmonary hypertension and keep results from his/her last pulmonary function test, chest imaging, echocardiogram and stress test

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• active ILD scleroderma

Exclusion Criteria:

• abnormal liver enzymes renal impairment neutropenia <1000 cells/mm3 thrombocytopenia < 50,000 cells/mm3